1196049-18-9

Usage

Uses

Used in Pharmaceutical Industry:
(-)-(R)-7-bromo-2,3-dihydro-1H-inden-1-ol is used as a building block for the synthesis of various pharmaceutical products due to its unique chiral structure and potential biological activities, including antitumor and antiparasitic properties.
Used in Agrochemical Industry:
(-)-(R)-7-bromo-2,3-dihydro-1H-inden-1-ol is used as a building block for the synthesis of agrochemical products, contributing to the development of effective and targeted pest control solutions.
Used in Organic Synthesis:
(-)-(R)-7-bromo-2,3-dihydro-1H-inden-1-ol is used as a reagent in organic synthesis, taking advantage of its unique chiral structure to create enantioselective reactions and produce desired chiral compounds.
Used in Chemical Reactions:
(-)-(R)-7-bromo-2,3-dihydro-1H-inden-1-ol is utilized in chemical reactions as a reagent, leveraging its specific properties to facilitate desired transformations and syntheses in the chemical research and development process.

Upstream product

• 124-73-2 1,2-dibromo-1,1,2,2-tetrafluoroethane 
• 125114-77-4 7-bromo-2,3-dihydro-1H-inden-1-one 
• 6351-10-6 1-Indanol 

Downstream Products

• 125114-77-4 7-bromo-2,3-dihydro-1H-inden-1-one 

Relevant academic research and scientific papers

The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H -inden-4-yl)pyridin-2-yl)-5-methyl-1 H -pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma

Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound (+)-23, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation.

QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF

Quinolinyldiamido transition metal complexes are disclosed for use in alkene polymerization to produce multimodal polyolefins.

INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

TRANSITION METAL COMPOUND, CATALYST COMPOSITION COMPRISING THE SAME, AND METHOD FOR PREPARING OLEFIN POLYMER USING THE SAME

According to the present invention, provided is a transition metal compound which is highly reactivity to hydrogen and has a structure showing high selectivity to optical isomers among various stereoisomers during synthesis. Moreover, provided are a catalyst composition containing the same, and a method for producing an olefin polymer using the catalyst composition. The use of the transition metal compound of the present invention enables the production of olefin polymers which is ultra highly fluidic compared to existing catalysts with the same amount of hydrogen. Accordingly, it is possible to provide olefin polymers useful for producing melt-blown fibers by using the transition metal compound.COPYRIGHT KIPO 2017

INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Pyridyldiamido Transition Metal Complexes, Production and Use Thereof

Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization.

PYRIDYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF

Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization.